A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

A team at Children’s National Research and Innovation Campus is working on something new that could change the way we pinpoint pain, and how effectively we treat it. The technology could give hope to ...

Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.

In a new study published in the Journal of Southeast Asian Orthopaedics, marijuana oil significantly reduced knee pain and ...

Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials ...

Vertex stock plummeted Thursday after the company's non-opioid pain drug proved it's no better than a placebo in patients ...

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...

Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Vertex Pharmaceuticals announced results of a midstage trial of its non-opioid experimental painkiller in chronic back pain, ...

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...